Research on Optimal Strategy of Hypoglycemic Therapy for Cirrhosis With Diabetes
Status:
Recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
Poor blood glucose control in liver cirrhosis can aggravate the poor prognosis of patients.
Under the background of the increasing number of liver cirrhosis patients with metabolic
abnormalities, how to optimize treatment is particularly important. The traditional treatment
of diabetes at the stage of liver cirrhosis is limited to insulin intensive therapy, but the
incidence of hypoglycemia is high, blood sugar fluctuates greatly, and multiple injections
are required. Research shows that insulin therapy has an increased overall mortality compared
with non insulin therapy. We used metformin,Ryzodeg and an oral DDP IV enzyme inhibitor as
the core combination according to the special pathological mechanism of elevated blood
glucose in liver cirrhosis . After preliminary experiments, we found that the program was
stable and was not easy to have hypoglycemia, and there was no traditional risk of lactic
acid poisoning caused by metformin. We designed an open randomized controlled clinical study,
Compared with the traditional insulin intensive treatment scheme, this new combination scheme
was compared whether it could improve the blood glucose level, the incidence of hypoglycemia
and lactic acid level, the incidence of cirrhosis complications, and the long-term survival
rate of liver disease. This study is helpful to optimize the hypoglycemic treatment of
cirrhosis with diabetes, and improve the blood glucose and long-term prognosis, The positive
evidence of this study contributes to the consensus or guidelines for the treatment of
cirrhosis with diabetes.